Clinical course and prognostic factors of patients with dedifferentiated liposarcoma: a retrospective analysis

BMC Cancer

Table 4 Overview on the most frequently used first line palliative systemic therapies

First line therapy	Number of patients (%)	mPFS (months)^a	ORR (%)^b
Doxorubicin	51 (52.0)	2.1	11.8
Doxorubicin-ifosfamide	12 (12.2)	2.4	16.7
Experimental therapy^c	18 (18.4)	5.8	22.2
Others^d	17 (17.3)

^amedian progression-free survival, counted from start of systemic treatment
^boverall response rate
^cDocetaxel + gemcitabine + MORAB-004/placebo, doxorubicin + olaratumab, trabectedin + tTF-NGR, brigimadlin
^dothers: trabectedin, eribulin, ifosfamide, pazopanib, liposomal doxorubicin, cisplatin-etoposide, etoposide, cyclophosphamide, doxorubicin-dacarbazine

ISSN: 1471-2407